Positive News SentimentPositive NewsNASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis $3.91 -0.05 (-1.26%) Closing price 04:00 PM EasternExtended Trading$3.86 -0.05 (-1.23%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About SCYNEXIS Stock (NASDAQ:SCYX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SCYNEXIS alerts:Sign Up Key Stats Today's Range$3.78▼$3.9750-Day Range$3.96▼$5.6752-Week Range$3.53▼$9.12Volume69,669 shsAverage Volume137,439 shsMarket Capitalization$38.90 millionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingHold Company Overview SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing medicines for fungal infections. The company’s lead product is BREXAFEMME (ibrexafungerp), an oral, non-azole antifungal approved by the U.S. Food and Drug Administration for the treatment of vulvovaginal candidiasis and for reducing the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal adolescent females. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting glucan synthase, an enzyme required for the formation of fungal cell walls. SCYNEXIS has also investigated the medicine for other serious fungal infections, including invasive candidiasis and certain infections caused by drug-resistant fungi. The company’s development strategy has centered on addressing unmet needs where existing antifungal therapies may be limited by resistance, tolerability, drug interactions, or routes of administration. Founded in 1999 and headquartered in Jersey City, New Jersey, SCYNEXIS serves the U.S. market through its commercial activities and has pursued partnerships and regulatory development opportunities internationally. The company’s operations are primarily focused on advancing and supporting ibrexafungerp and related antifungal research.AI Generated. May Contain Errors. Read More SCYNEXIS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreSCYX MarketRank™: 3.177423569375 of 5 starsSCYNEXIS scored higher than 64% of companies evaluated by MarketBeat, and ranked 330th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingSCYNEXIS has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSCYNEXIS has a consensus price target of $33.00, representing about 752.7% upside from its current price of $3.87.Amount of Analyst CoverageSCYNEXIS has only been the subject of 3 research reports in the past 90 days.Read more about SCYNEXIS's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SCYNEXIS are expected to grow in the coming year, from ($1.60) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about SCYNEXIS's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.23% of the float of SCYNEXIS has been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 0.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SCYNEXIS has recently increased by 29.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentSCYNEXIS has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for SCYNEXIS this week, compared to 2 articles on an average week.Search Interest6 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by Insiders4.09% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SCYNEXIS's insider trading history. Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCYX Stock News HeadlinesSCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney DiseaseOctober 7, 2026 | marketscreener.comMSCYNEXIS (NASDAQ:SCYX) Shares Cross Above Fifty Day Moving Average - What's Next?October 7, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 15 at 1:00 AM | Stansberry Research (Ad)SCYNEXIS Reports Favorable Phase 1 Results For ADPKD DrugOctober 6, 2026 | rttnews.comSCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...October 6, 2026 | markets.businessinsider.comSCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026October 6, 2026 | quiverquant.comQSCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 6, 2026 | globenewswire.comSCYNEXIS Secures BARDA Funding for Antifungal PipelineSeptember 30, 2026 | theglobeandmail.comSee More Headlines SCYX Stock Analysis - Frequently Asked Questions How have SCYX shares performed this year? SCYNEXIS's stock was trading at $5.0592 on January 1st, 2026. Since then, SCYX shares have decreased by 23.5% and is now trading at $3.87. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) posted its quarterly earnings results on Monday, August, 10th. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of ($0.51) by $1.14. The business earned $0.24 million during the quarter, compared to analysts' expectations of $0.08 million. When did SCYNEXIS's stock split? SCYNEXIS shares reverse split on the morning of Monday, June 1st 2026.The 1-8 reverse split was announced on Friday, May 22nd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did SCYNEXIS IPO? SCYNEXIS (SCYX) raised $62 million in an initial public offering (IPO) on Thursday, April 3rd 2014. The company issued 6,200,000 shares at $10.00 per share. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Matinas Biopharma (MTNB), NVIDIA (NVDA), Micron Technology (MU), Viking Therapeutics (VKTX) and NIO (NIO). Company Calendar Last Earnings8/10/2026Today10/15/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SCYX's financial health is in the Red zone, according to TradeSmith. SCYX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SCYX CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees29Year Founded2000Price Target and Rating Average Price Target for SCYNEXIS$33.00 High Price Target$33.00 Low Price Target$33.00 Potential Upside/Downside+744.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.61 million Net MarginsN/A Pretax Margin-53.27% Return on Equity-44.15% Return on Assets-32.61% Debt Debt-to-Equity RatioN/A Current Ratio9.65 Quick Ratio9.65 Sales & Book Value Annual Sales$20.60 million Price / Sales1.89 Cash FlowN/A Price / Cash FlowN/A Book Value$9.07 per share Price / Book0.43Miscellaneous Outstanding Shares9,950,000Free Float9,543,000Market Cap$38.90 million OptionableOptionable Beta1.06 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:SCYX) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
